End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.7 TWD | 0.00% | -1.52% | +13.50% |
Apr. 15 | Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Sales 2022 | 512M 15.73M | Sales 2023 | 890M 27.34M | Capitalization | 4.46B 137M |
---|---|---|---|---|---|
Net income 2022 | -28M -860K | Net income 2023 | 22M 676K | EV / Sales 2022 | 8.44 x |
Net Debt 2022 | 411M 12.63M | Net Debt 2023 | 604M 18.55M | EV / Sales 2023 | 5.69 x |
P/E ratio 2022 |
-136
x | P/E ratio 2023 |
200
x | Employees | 173 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 15.26% |
1 week | -1.52% | ||
Current month | +5.58% | ||
1 month | +11.27% | ||
3 months | +4.61% | ||
6 months | +18.23% | ||
Current year | +13.50% |
Managers | Title | Age | Since |
---|---|---|---|
Chi Tai Chang
CEO | Chief Executive Officer | - | - |
Chia Ying Chen
DFI | Director of Finance/CFO | - | - |
Meng Lin Tsai
BRD | Director/Board Member | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Cheng Hung Tsai
CHM | Chairman | - | 08-01-14 |
Wei Chao Kao
BRD | Director/Board Member | - | - |
Kang Chi Chou
BRD | Director/Board Member | - | 19-06-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 22.7 | 0.00% | 1,005 |
24-04-24 | 22.7 | +0.89% | 18,572 |
24-04-23 | 22.5 | 0.00% | 12,113 |
24-04-22 | 22.5 | +0.67% | 24,202 |
24-04-19 | 22.35 | -3.04% | 84,869 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+13.50% | 155M | |
+24.98% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.51% | 233B | |
+5.61% | 201B | |
-10.22% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- 4166 Stock